19 patents
Utility
TL1A Patient Selection Methods, Systems, and Devices
31 Aug 23
Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent.
Laurens KRUIDENIER, Mahyar SABRIPOUR, Janine BILSBOROUGH, Dermot P. MCGOVERN, Dalin LI
Filed: 13 Feb 23
Utility
Methods, Systems, and Kits for Treatment of Inflammatory Diseases Targeting TL1A
31 Aug 23
Provided are methods, systems, and kits for selecting a subject for treatment with an inhibitor of Tumor necrosis factor-like cytokine 1A (TL1A) activity or expression based on a presence of one or more genotypes associated with a positive therapeutic response to the inhibitor of TL1A.
Laurens KRUIDENIER, Mahyar SABRIPOUR, Jeffry D. Watkins, Cindy T. DICKERSON, Rafael ROJAS, Matthew REISSMAN, Patricia MCNEELEY, Janine BILSBOROUGH, Dermot P. MCGOVERN, Dalin LI
Filed: 12 May 23
Utility
Therapeutic Agents Targeting GPR35
18 May 23
Described herein are GPR35 modulators and methods of using these compounds in the treatment of diseases, disorders or conditions.
Robert HIGUCHI, Michael BISHOP
Filed: 20 Jan 23
Utility
ANTI-CD30L Antibodies and Uses Thereof
2 Mar 23
Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).
Jessie-Farah FECTEAU, Mark RENSHAW, Johan FRANSSON, Olivier LAURENT, Burton BARNETT
Filed: 26 Aug 22
Utility
TL1A Patient Selection Methods, Systems, and Devices
19 Jan 23
Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent.
Laurens KRUIDENIER, Mahyar SABRIPOUR, Janine BILSBOROUGH, Dermot P. MCGOVERN, Dalin LI
Filed: 23 Aug 21
Utility
Humanized Antibodies to Tnf-like Ligand 1A (TL1A) and Uses Thereof
18 Aug 22
Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
Jeffry D. Watkins, Cindy T. Dickerson, Rafael Rojas, Matthew Reissman, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
Filed: 28 Feb 22
Utility
GPR35 Modulators
9 Dec 21
Described herein are GPR35 modulators and methods of using these compounds in the treatment of diseases, disorders or conditions.
Robert Higuchi
Filed: 18 May 21
Utility
Methods and Systems for Selection and Treatment of Patients with Inflammatory Diseases
5 Aug 21
Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody.
Janine BILSBOROUGH, Dermot P. MCGOVERN, Stephan TARGAN, Alka POTDAR, Jeffry D. WATKINS, Cindy T. DICKERSON
Filed: 26 Apr 19
Utility
Humanized Antibodies to Tnf-like Ligand 1A (TL1A) and Uses Thereof
29 Apr 21
Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
Jeffry D. Watkins, Cindy T. Dickerson, Rafael Rojas, Matthew Reissman, Patricia McNeeley
Filed: 2 Dec 20
Utility
TL1A Patient Selection Methods, Systems, and Devices
8 Apr 21
Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent.
Laurens KRUIDENIER, Mahyar SABRIPOUR, Janine BILSBOROUGH, Dermot P. MCGOVERN, Dalin LI
Filed: 10 Dec 20
Utility
Optimized ANTI-TL1A Antibodies
11 Mar 21
Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohns Disease (CD) and ulcerative colitis (UC).
Jeffry D. WATKINS, Cindy T. DICKERSON, J. Monty WATKINS, Patricia MCNEELEY
Filed: 24 Apr 19
Utility
TL1A Patient Selection Methods, Systems, and Devices
18 Nov 20
Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent.
Laurens KRUIDENIER, Mahyar SABRIPOUR
Filed: 12 May 20
Utility
Methods for Assessing Mucosal Healing In Crohn's Disease Patients
19 Aug 20
of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient.
Anjali JAIN, Venkateswarlu KONDRAGUNTA, Michael Hale
Filed: 30 May 18
Utility
Optimized ANTI-TL1A Antibodies
12 Aug 20
Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins
Filed: 29 Apr 20
Utility
GPR35 Modulators
29 Jul 20
Described herein are GPR35 modulators and methods of using these compounds in the treatment of diseases, disorders or conditions.
Robert Higuchi
Filed: 22 Jan 20
Utility
Methods for Monitoring Vedolizumab Treatment
29 Jul 20
The disclosure provides a method for predicting that a subject having inflammatory bowel disease (IBD) will have a clinical response or remission to an anti-α4β7 integrin during the course of therapy by assessing the concentration of the anti-α4β7 integrin drug at the induction or maintenance phase, respectively in a sample from the subject.
Snehal U. NAIK, Anjali JAIN
Filed: 8 Oct 18
Utility
Optimized ANTI-TL1A Antibodies
20 May 20
Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins
Filed: 24 Nov 19
Utility
Methods for Prediction of Anti-tnf Alpha Drug Levels and Autoantibody Formation
20 May 20
In some aspects, the present invention provides methods for predicting whether a subject will develop autoantibodies to an anti-TNF drug during the course of anti-TNFα drug therapy.
Sharat Singh, Venkateswarlu Kondragunta
Filed: 17 Nov 19
Utility
Indirect Homogeneous Mobility Shift Assays for the Detection of Biologics In Patient Samples
18 Mar 20
The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample.
Jared Salbato, Stefan Westin, Nicholas Chi-Kwan Ling, Anjali Jain, Sharat Singh
Filed: 8 Aug 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first